Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RG547 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| RG547 | DRUG | Administered iv on days 1 and 8 of a 3 week cycle at escalating doses to successive groups of patients until MTD is reached. |
Inclusion Criteria: * adult patients, \>=18 years of age; * locally advanced or metastatic solid tumors; * measurable or evaluable disease. Exclusion Criteria: * prior chemotherapy, radiotherapy or immunotherapy within 3 weeks of start of study; * prior history of CNS metastases with disease prog...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
RG547 is an investigational small molecule being studied for the treatment of neoplasms, which are abnormal growths of tissue that can be benign or malignant. It is being developed as a potential oncology therapy for patients with advanced solid tumors.
RG547 is being developed by Roche Holding AG, a multinational healthcare company. Roche's stock is traded over-the-counter under the ticker symbol RHHBY. The company is conducting clinical research to evaluate the safety and efficacy of this investigational drug.
RG547 is in Phase 1 clinical development. It has completed a Phase 1 trial, meaning it is still in the early stages of clinical investigation. As an investigational drug, it has not yet been approved by regulatory authorities and remains under study to assess its safety and potential benefits.
RG547 has one completed clinical trial registered under NCT00400296, titled "A Study of R547 in Patients With Advanced Solid Tumors." This Phase 1 study enrolled 58 participants in the United States and evaluated the drug in patients with neoplasms, with no control group.
RG547 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial, but it has not received marketing authorization from the U.S. Food and Drug Administration or any other regulatory agency. The drug remains in clinical development and is not available for commercial use.